Villaris Therapeutics
Company Details
About: Villaris Therapeutics is a preclinical-stage biopharmaceutical company focused on developing novel antibody therapeutics for the treatment of vitiligo.
A recent discovery revealed that an immune pathway, initiated by IL-15 signaling and its formation of autoimmune memory T cells (TRM), was responsible for the return of vitiligo usually soon after stopping treatments. Targeting this pathway therapeutically was very effective at reversing the disease in a mouse model of vitiligo with long-lasting results.
Villaris Therapeutics is developing a novel humanized anti-IL-15R antibody to target depletion of TRM for the effective and durable treatment of vitiligo and other tissue-specific autoimmune diseases that also involve these cells.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Villaris Therapeutics | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.